BR112022012365A2 - Tratamento de lesão cerebral traumática leve - Google Patents
Tratamento de lesão cerebral traumática leveInfo
- Publication number
- BR112022012365A2 BR112022012365A2 BR112022012365A BR112022012365A BR112022012365A2 BR 112022012365 A2 BR112022012365 A2 BR 112022012365A2 BR 112022012365 A BR112022012365 A BR 112022012365A BR 112022012365 A BR112022012365 A BR 112022012365A BR 112022012365 A2 BR112022012365 A2 BR 112022012365A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- brain injury
- traumatic brain
- mild traumatic
- mtbi
- Prior art date
Links
- 208000007333 Brain Concussion Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000002459 sustained effect Effects 0.000 abstract 2
- 102000012004 Ghrelin Human genes 0.000 abstract 1
- 101800001586 Ghrelin Proteins 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 abstract 1
- 230000000116 mitigating effect Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Compounds Of Unknown Constitution (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962953130P | 2019-12-23 | 2019-12-23 | |
| PCT/US2020/066703 WO2021133844A1 (en) | 2019-12-23 | 2020-12-22 | Treatment of mild traumatic brain injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022012365A2 true BR112022012365A2 (pt) | 2022-08-30 |
Family
ID=76575665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022012365A BR112022012365A2 (pt) | 2019-12-23 | 2020-12-22 | Tratamento de lesão cerebral traumática leve |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230031262A1 (https=) |
| EP (1) | EP4081238A4 (https=) |
| JP (1) | JP2023508250A (https=) |
| KR (1) | KR20220122691A (https=) |
| CN (1) | CN114980915A (https=) |
| AU (1) | AU2020412765A1 (https=) |
| BR (1) | BR112022012365A2 (https=) |
| CA (1) | CA3165738A1 (https=) |
| IL (1) | IL294156A (https=) |
| MX (1) | MX2022007844A (https=) |
| WO (1) | WO2021133844A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220370804A1 (en) * | 2021-01-22 | 2022-11-24 | The Regents Of The University Of Colorado, A Body Corporate | Motor learning and vagus nerve stimulation (vns) paired with motor learning to treat demyelinating diseases, conditions and disorders |
| CN113723530B (zh) * | 2021-09-02 | 2022-03-25 | 中国科学院自动化研究所 | 基于视频分析和电子心理沙盘的智能心理评估系统 |
| AU2023338304A1 (en) * | 2022-09-07 | 2025-04-10 | Oxeia Biopharmaceuticals, Inc. | Treatment of mild traumatic brain injury |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6545697B2 (ja) * | 2013-11-15 | 2019-07-17 | ニューラル・アナリティクス・インコーポレーテッド | 神経学的状態の診断のための脳の血流速度の構造的特徴をモニタリングすること |
| US9119832B2 (en) * | 2014-02-05 | 2015-09-01 | The Regents Of The University Of California | Methods of treating mild brain injury |
| WO2015168103A1 (en) * | 2014-04-29 | 2015-11-05 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
| AU2015305647A1 (en) * | 2014-08-19 | 2017-04-06 | Oxeia Biopharmaceuticals, Inc. | Methods of treating mild brain injury |
| WO2016134215A1 (en) * | 2015-02-19 | 2016-08-25 | The Regents Of The University Of California | Methods of treating mild brain injury and post-traumatic stress disorder |
| US20180071367A1 (en) * | 2015-03-09 | 2018-03-15 | Oxeia Biopharmaceuticals, Inc. | Methods of treating cognitive impairments or dysfunction |
| WO2017075535A1 (en) * | 2015-10-28 | 2017-05-04 | Oxeia Biopharmaceuticals, Inc. | Methods of treating neurodegenerative conditions |
-
2020
- 2020-12-22 BR BR112022012365A patent/BR112022012365A2/pt not_active Application Discontinuation
- 2020-12-22 WO PCT/US2020/066703 patent/WO2021133844A1/en not_active Ceased
- 2020-12-22 EP EP20905518.5A patent/EP4081238A4/en active Pending
- 2020-12-22 AU AU2020412765A patent/AU2020412765A1/en active Pending
- 2020-12-22 KR KR1020227025653A patent/KR20220122691A/ko not_active Withdrawn
- 2020-12-22 CA CA3165738A patent/CA3165738A1/en active Pending
- 2020-12-22 IL IL294156A patent/IL294156A/en unknown
- 2020-12-22 JP JP2022564096A patent/JP2023508250A/ja active Pending
- 2020-12-22 CN CN202080092650.7A patent/CN114980915A/zh active Pending
- 2020-12-22 US US17/787,848 patent/US20230031262A1/en active Pending
- 2020-12-22 MX MX2022007844A patent/MX2022007844A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN114980915A (zh) | 2022-08-30 |
| CA3165738A1 (en) | 2021-07-01 |
| JP2023508250A (ja) | 2023-03-01 |
| US20230031262A1 (en) | 2023-02-02 |
| AU2020412765A1 (en) | 2022-07-14 |
| WO2021133844A1 (en) | 2021-07-01 |
| EP4081238A4 (en) | 2023-08-30 |
| EP4081238A1 (en) | 2022-11-02 |
| MX2022007844A (es) | 2022-09-07 |
| IL294156A (en) | 2022-08-01 |
| KR20220122691A (ko) | 2022-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022012365A2 (pt) | Tratamento de lesão cerebral traumática leve | |
| MX2019012818A (es) | Metodos para mejorar la memoria y la cognicion y para el tratamiento de trastornos de la memoria y cognitivos. | |
| BR112017004679A2 (pt) | dispositivos, sistemas e métodos de fototerapia com múltiplos comprimentos de onda para o tratamento não invasivo de tecido danificado ou doente | |
| CL2017002825A1 (es) | Formulaciones de tpp1 y métodos para tratar la enfermedad de cln2 | |
| RU2016143979A (ru) | Схема дозирования модулятора s1p с немедленным высвобождением | |
| CL2021003312A1 (es) | Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma. | |
| BR112016015490A2 (pt) | Aparelho, que inclui uma fonte de luz, para tratamento endoscópico ou intracraniano | |
| CL2019000778A1 (es) | Derivados de cromano, isocromano y dihidroisobenzofuranos como moduladores alostéricos negativos de mglur2, composiciones y su uso. | |
| MX391627B (es) | Aplicación cuantitativa periorbital de fármacos oftalmológicos. | |
| CO2022005783A2 (es) | Inhibidores de los receptores a₂c adrenérgicos | |
| BR112022020020A2 (pt) | Métodos de tratamento da doença do coronavírus 2019 | |
| CO2022007273A2 (es) | Análogos de insulina novedosos y usos de estos | |
| BR112023019795A2 (pt) | Composições nasais compreendendo alcaftadina | |
| BR112021023251A2 (pt) | Tratamento da doença ocular | |
| CO6290669A2 (es) | Usos terapeuticos de compuestos que tiene afinidad con el transportador de serotonina los receptores de serotonina y transportador de noraadrenalina | |
| BR112023003432A2 (pt) | Regime de tratamento para o tratamento de doenças autoimunes | |
| BR112022017998A2 (pt) | Formulações de liberação controlada compreendendo drotaverina ou sal da mesma | |
| PE20241236A1 (es) | Composiciones y metodos para tratar pacientes con demencia debida a la enfermedad de alzheimer con una combinacion de thc y melatonina | |
| WO2024054875A3 (en) | Treatment of mild traumatic brain injury | |
| Germonpre et al. | ENT indications for hyperbaric oxygen therapy | |
| BR112021020698A2 (pt) | Combinação terapêutica compreendendo um agonista ffar4 e um agonista nachr alpha-7 ou modulador positivo | |
| MX2020013306A (es) | Uso de compuestos de halogeno para el tratamiento y prevencion de lesiones tisulares y sindrome post-cuidados intensivos. | |
| Iranzo et al. | Rapid eye movement sleep behaviour | |
| PY2459326A (es) | Composición farmacéutica orodispersable de clonazepam | |
| BR112018017167A2 (pt) | titulação de cebranopadol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |